Hazzard A, McCrorey M, Salman T, Johnson D, Luo Z, Fu X
NeuroImmune Pharm Ther. 2025; 3(3-4):183-193.
PMID: 39741560
PMC: 11683879.
DOI: 10.1515/nipt-2024-0012.
Schoeler T, Baldwin J, Martin E, Barkhuizen W, Pingault J
Nat Ment Health. 2024; 2(7):865-876.
PMID: 39005547
PMC: 11236708.
DOI: 10.1038/s44220-024-00261-x.
Fordjour E, Manful C, Sey A, Javed R, Pham T, Thomas R
Front Pharmacol. 2023; 14:1200269.
PMID: 37397476
PMC: 10308385.
DOI: 10.3389/fphar.2023.1200269.
Schnell T, Gromm C, Klockner N
Sci Rep. 2023; 13(1):709.
PMID: 36639397
PMC: 9839715.
DOI: 10.1038/s41598-023-27592-6.
Moran M, Heaton L, Leroux B, Flake N
Anesth Prog. 2022; 69(4):15-21.
PMID: 36534774
PMC: 9773404.
DOI: 10.2344/anpr-69-02-08.
Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis.
Schoeler T, Ferris J, Winstock A
Transl Psychiatry. 2022; 12(1):369.
PMID: 36068202
PMC: 9448725.
DOI: 10.1038/s41398-022-02112-8.
Remote detection of Cannabis-related impairments in performance?.
Phillips J, Ogeil R
Psychopharmacology (Berl). 2022; 239(8):2527-2536.
PMID: 35451615
DOI: 10.1007/s00213-022-06145-1.
Acute effects of oral delta-9-tetrahydrocannabinol (THC) on autonomic cardiac activity and their relation to subjective and anxiogenic effects.
Pabon E, Rockwood F, Norman G, de Wit H
Psychophysiology. 2021; 59(2):e13955.
PMID: 34665890
PMC: 8724445.
DOI: 10.1111/psyp.13955.
Investigating the Residual Effects of Chronic Cannabis Use and Abstinence on Verbal and Visuospatial Learning.
Lorenzetti V, Takagi M, van Dalen Y, Yucel M, Solowij N
Front Psychiatry. 2021; 12:663701.
PMID: 34220577
PMC: 8247947.
DOI: 10.3389/fpsyt.2021.663701.
Sex differences in the acute effects of oral and vaporized cannabis among healthy adults.
Sholler D, Strickland J, Spindle T, Weerts E, Vandrey R
Addict Biol. 2020; 26(4):e12968.
PMID: 32985064
PMC: 8855307.
DOI: 10.1111/adb.12968.
Delineating the Psychic Structure of Substance Use and Addictions, from Neurobiology to Clinical Implications: Ten Years Later.
Pani P, Maremmani A, Pacini M, Trogu E, Gessa G, Ruiz P
J Clin Med. 2020; 9(6).
PMID: 32570932
PMC: 7356689.
DOI: 10.3390/jcm9061913.
Do AKT1, COMT and FAAH influence reports of acute cannabis intoxication experiences in patients with first episode psychosis, controls and young adult cannabis users?.
Hindocha C, Quattrone D, Freeman T, Murray R, Mondelli V, Breen G
Transl Psychiatry. 2020; 10(1):143.
PMID: 32398646
PMC: 7217850.
DOI: 10.1038/s41398-020-0823-9.
Targeting Peripherally Restricted Cannabinoid Receptor 1, Cannabinoid Receptor 2, and Endocannabinoid-Degrading Enzymes for the Treatment of Neuropathic Pain Including Neuropathic Orofacial Pain.
Hossain M, Ando H, Unno S, Kitagawa J
Int J Mol Sci. 2020; 21(4).
PMID: 32093166
PMC: 7073137.
DOI: 10.3390/ijms21041423.
The Cardiovascular Effects of Marijuana: Are the Potential Adverse Effects Worth the High?.
Subramaniam V, Menezes A, DeSchutter A, Lavie C
Mo Med. 2019; 116(2):146-153.
PMID: 31040502
PMC: 6461323.
Are cannabis-using and non-using patients different groups? Towards understanding the neurobiology of cannabis use in psychotic disorders.
Sami M, Bhattacharyya S
J Psychopharmacol. 2018; 32(8):825-849.
PMID: 29591635
PMC: 6058406.
DOI: 10.1177/0269881118760662.
Toward the Identification of a Specific Psychopathology of Substance Use Disorders.
Maremmani A, Pani P, Rovai L, Bacciardi S, Maremmani I
Front Psychiatry. 2017; 8:68.
PMID: 28496418
PMC: 5406468.
DOI: 10.3389/fpsyt.2017.00068.
Behavioral Determinants of Cannabinoid Self-Administration in Old World Monkeys.
John W, Martin T, Nader M
Neuropsychopharmacology. 2017; 42(7):1522-1530.
PMID: 28059083
PMC: 5436120.
DOI: 10.1038/npp.2017.2.
Vulnerability Factors for the Psychiatric and Behavioral Effects of Cannabis.
Bortolato M, Bini V, Tambaro S
Pharmaceuticals (Basel). 2016; 3(9):2799-2820.
PMID: 27713377
PMC: 4034098.
DOI: 10.3390/ph3092799.
Cannabis and development of dual diagnoses: A literature review.
Hanna R, Perez J, Ghose S
Am J Drug Alcohol Abuse. 2016; 43(4):442-455.
PMID: 27612527
PMC: 5344774.
DOI: 10.1080/00952990.2016.1213273.
Psychopathological symptoms of patients with heroin addiction entering opioid agonist or therapeutic community treatment.
Pani P, Trogu E, Vigna-Taglianti F, Mathis F, Diecidue R, Kirchmayer U
Ann Gen Psychiatry. 2014; 13(1):35.
PMID: 25435897
PMC: 4247563.
DOI: 10.1186/s12991-014-0035-x.